Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Charles River unveiled its refreshed Pathway to Purpose strategy at its 2026 Investor Day, targeting modernization, a strengthened scientific portfolio, and a client-centric operating model. The company reaffirmed 2026 guidance with revenue and non-GAAP EPS ($11.15-$11.45) now expected at the upper ends of prior ranges, and introduced 2030 targets of 5%-7% organic revenue CAGR and ~24% non-GAAP operating margin.
Key figures
- Guidance
- 2026 revenue and non-GAAP EPS at upper ends of prior ranges; non-GAAP operating margin 21.0%-21.3%; non-GAAP EPS $11.15-$11.45; long-term targets: 5%-7% organic revenue CAGR 2027-2030, ~24% non-GAAP operating margin by 2030, low-double-digit non-GAAP EPS CAGR 2027-2030
- Apollo client users
- more than 18,000
- Cumulative savings 2027 2030
- over $300 million
- Bioanalysis revenue 2030 target
- approximately $450 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.